Navigation Links
Blood vessel forming potential of stem cells from human placenta and umbilical cord blood
Date:7/19/2012

Tampa, Fla. (July 19, 2012) A study comparing whether endothelial colony-forming cells (ECFCs) derived from human placenta or those derived from human umbilical cord blood are more proliferative and better for forming new blood vessels has found that ECFCs derived from human placenta are more vasculogenic.

The study, carried out by researchers at the Indiana School of Medicine, is published in a recent issue of Cell Medicine [2(3)] and is freely available on-line at: http://www.ingentaconnect.com/content/cog/cm.

"Circulating ECFCs isolated from umbilical cord blood and those isolated from human placenta are phenotypically identical and have equivalent proliferative potential," said study lead author Michael P. Murphy, MD of the Indiana University's Department of Surgery. "After transplantation, the circulating placenta-derived ECFCs formed significantly more blood vessels in vivo than the ECFCs derived from umbilical cord blood, indicating not only that there are inherent functional differences between resident and circulating ECFC populations, but that the placenta-derived cells are more vasculogenic."

Umbilical cord blood and the extra-embryonic membranes of placenta are ideal sources of progenitor cells, said the researchers, because the tissues are discarded as medical waste and ethical concerns facing embryonic stem cells are avoided. The quantity of cells that can be derived from placenta, however, is much greater than the amount that can be derived from umbilical cord blood, making the placenta the more abundant source.

They concluded that the placenta represents an abundant source of ECFCs that could provide a therapeutic dose of cells.

"The potential volume of placenta-derived ECFCs that can be harvested from a single placenta would provide a sufficient dose of cells without the necessity of expansion," noted Murphy.

According to the researchers, the role of circulating ECFCs has yet to be determined, yet circulating mature endothelial cells are rarely found in normal, healthy individuals as they are markers of vascular damage, remodeling and dysfunction.

"We envision that placenta-derived ECFCs may provide some benefit in neonatal cerebral ischema or can be used for tissue banking for future and be useful in treating cardiovascular disease," said Murphy and his colleagues.


'/>"/>

Contact: David Eve
cellmedicinect@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. True blood: SLU scientist investigates clotting factors
2. Dinosaurs were warm-blooded reptiles
3. Blood-brain barrier building blocks forged from human stem cells
4. Boosting blood system protein complex protects against radiation toxicity
5. New study: Snacking on raisins significantly reduces overall post-meal blood sugar levels
6. Manipulating chromatin loops to regulate genes may offer future treatments for blood diseases
7. Common genetic mutation increases sodium retention, blood pressure
8. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
9. New microscope uses rainbow of light to image the flow of individual blood cells
10. VolitionRX Raises Over $1 Million To Begin Clinical Trials of Blood Based Diagnostic Tests
11. Leeches are DNA bloodhounds in the jungle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology: